At a Glance
What it is: A pre-blended single vial containing four separately studied peptides: BPC-157, TB-500 (full-length thymosin beta-4), GHK-Cu, and KPV.
Research areas: soft-tissue and tendon repair in animals (BPC-157), wound closure and new blood vessel growth (TB-500), matrix remodeling and repair signaling in connective-tissue cells (GHK-Cu), and inflammatory signaling in gut and immune cells (KPV).
Evidence level: Each compound has its own preclinical literature, mostly animal and lab-dish work, with a small amount of human data on Thymosin Beta-4. There is no controlled trial of the four compounds together.
The short version: KLOW is four peptides in one vial. Each has been studied on its own, and this page summarizes that work compound by compound. What has not been studied is the combination. No trial has tested these four together, in any species, so anything said about how they behave as a group is inference rather than evidence. That gap is stated here rather than papered over.
On this page: What KLOW is made of · Quick facts · What the research found · How it works · Limits · Common questions
KLOW is a blend, not a compound. It is four separate peptides supplied pre-mixed in a single vial, and each of the four carries its own research history that has nothing to do with the other three.
That structure shapes what an honest page can say. Below is what researchers looked at for each component, in what kind of model, and what they observed. Then a section on what the combination does not have, which is the part most pages in this category skip.
What KLOW is made of
Four peptides, each with a separate literature and a separate page on this site:
- BPC-157, a synthetic 15-amino-acid peptide whose sequence comes from a protein found in human gastric juice. Most of its research is on soft-tissue repair in animals. Full research summary
- TB-500, which in this blend is full-length thymosin beta-4, a 43-amino-acid peptide found in nearly all cells, where it binds actin. Its research centers on wound closure. It is not the short seven-amino-acid fragment that is sometimes sold under the same name. Full research summary
- GHK-Cu, the tripeptide GHK (glycyl-L-histidyl-L-lysine) bound to a copper ion. Its research is mostly on matrix remodeling in connective-tissue cells. Full research summary
- KPV, the three-amino-acid tail of the hormone alpha-MSH. Its research is on inflammatory signaling. Full research summary
This page does not restate the amount of each. What follows is the research on each compound as a compound.
Quick facts
- Names: KLOW, KLOW Blend. The name is a vendor label for this four-part blend, not a compound or a drug name.
- What it is: four peptides in one lyophilized vial, 80mg total. BPC-157 is C62H98N16O22, 1419.5 g/mol (PubChem CID 9941957). TB-500 here is full-length thymosin beta-4 (timbetasin), C212H350N56O78S, 4963 g/mol (PubChem CID 16132341). The GHK peptide is C14H24N6O4, 340.4 g/mol without its copper (PubChem CID 73587), and PubChem lists the copper complex as prezatide copper (CID 71587328). KPV is C16H30N4O4, 342.4 g/mol (PubChem CID 125672).
- Evidence: we found no published study of all four together (PubMed, searched 24 September 2026). One 2026 rat study tested two of them, BPC-157 and TB-500, together (Biçer et al., 2026). For BPC-157 alone, a 2025 systematic review found 35 of 36 musculoskeletal studies were in animals or cells (Vasireddi et al., 2025). Full-length thymosin beta-4 has reached small Phase 2 human trials (Sosne and Ousler, 2015). The GHK-Cu and KPV studies cited below are cell and mouse work.
- Approval: we found no drug approval anywhere for KLOW or for any of its four components. For BPC-157, the FDA says it lacks sufficient information to know whether it would cause harm in people (FDA).
KLOW research: what the studies on each component found, and what they didn’t
Every study below tested one compound, or in the last case two, never all four. Most used rats, mice or cells in a dish. The human data is on full-length thymosin beta-4 only, and it is small.
BPC-157
Ligament healing in rats (Journal of Orthopaedic Research, 2010). Researchers cut the knee ligament in rats and gave BPC-157 by several routes over 90 days. They observed better functional recovery and better structural healing in the treated animals. Live animal model, not people. PMID 20225319. https://pubmed.ncbi.nlm.nih.gov/20225319/
Achilles tendon-to-bone healing in rats (Journal of Orthopaedic Research, 2006). This study looked at how a detached Achilles tendon reattached to bone in rats. Treated animals healed faster, and BPC-157 offset some of the harm corticosteroids caused in that model. PMID 16583442. https://pubmed.ncbi.nlm.nih.gov/16583442/
Review of the soft-tissue research (Cell and Tissue Research, 2019). A review pulled together the musculoskeletal studies and reported consistent healing effects across the animal work. The authors were clear that the evidence is preclinical and that human efficacy is not confirmed. PMID 30915550. https://pubmed.ncbi.nlm.nih.gov/30915550/
TB-500 (full-length thymosin beta-4)
Wound healing in rats (Journal of Investigative Dermatology, 1999). Researchers applied thymosin beta-4 to full-thickness wounds in rats, on the wound and by injection into the abdomen. New surface cover over the wound rose 42% over saline at day 4 and up to 61% at day 7, and treated wounds shrank at least 11% more by day 7. In a separate lab-dish test, the cells that cover a wound moved 2 to 3 times more. PMID 10469335. https://pubmed.ncbi.nlm.nih.gov/10469335/
Dry eye trial in people (Clinical Ophthalmology, 2015). A Phase 2, double-masked, placebo-controlled trial in 72 adults with moderate to severe dry eye, using a 0.1% thymosin beta-4 eye solution or placebo for 28 days. Neither main measure, eye discomfort or lower corneal staining at day 29, differed from placebo. Some secondary measures did. PMID 26056426. https://pubmed.ncbi.nlm.nih.gov/26056426/
Venous ulcer trial design (Annals of the New York Academy of Sciences, 2007). A report describing a planned randomized, placebo-controlled study of thymosin beta-4 on venous leg ulcers, designed for 72 patients over 84 days at 10 sites in Italy and Poland. When the paper was written, 21 patients had been enrolled, and it reports no results. PMID 17495250. https://pubmed.ncbi.nlm.nih.gov/17495250/
Wound-healing review (Vitamins and Hormones, 2016). A review of the thymosin beta-4 wound research, including Phase 2 results in patients with pressure ulcers, stasis ulcers, and wounds from a blistering genetic condition (epidermolysis bullosa), alongside animal work. PMID 27450738. https://pubmed.ncbi.nlm.nih.gov/27450738/
GHK-Cu
Copper and matrix remodeling in fibroblasts (Siméon, Life Sciences, 2000). An in vitro study using cultured fibroblasts, the cells that build connective tissue, in a lab dish. Researchers observed that GHK-Cu raised levels of MMP-2, an enzyme that reshapes the extracellular matrix, and raised two matrix inhibitors, TIMP-1 and TIMP-2. Copper ions alone reproduced the MMP-2 effect, and the GHK peptide alone did not. PMID 11045606. https://pubmed.ncbi.nlm.nih.gov/11045606/
Growth-factor expression in stressed fibroblasts (Pollard, Archives of Facial Plastic Surgery, 2005). An in vitro study of human fibroblasts, some taken from tissue that had been through radiation therapy, to model tissue injury. Treated cells doubled faster than untreated ones, and the irradiated cells made more of two repair signals, bFGF and VEGF, early after treatment. PMID 15655171. https://pubmed.ncbi.nlm.nih.gov/15655171/
Gene-expression review (Pickart and Margolina, International Journal of Molecular Sciences, 2018). A review built on gene-profiling data, mapping the pathways GHK appears to touch. This is an interpretation of prior data, not an experiment. PMID 29986520. https://pubmed.ncbi.nlm.nih.gov/29986520/
KPV
KPV uptake and gut inflammation (Gastroenterology, 2008). Researchers tested KPV in intestinal and immune cells and in two mouse colitis models. They reported that a transporter called PepT1 carried KPV into cells, where it lowered inflammatory signaling and cut pro-inflammatory cytokines. This mixes lab-dish cells and live animals, not people. PMID 18061177. https://pubmed.ncbi.nlm.nih.gov/18061177/
KPV in two colitis models (Inflammatory Bowel Diseases, 2008). A mouse study using DSS-induced colitis and a transfer colitis model. Treated mice recovered sooner and showed less inflammation in gut tissue. Live animal model. PMID 18092346. https://pubmed.ncbi.nlm.nih.gov/18092346/
Review of alpha-MSH and its tripeptides (Endocrine Reviews, 2008). A review, not a new experiment. The authors described consistent anti-inflammatory effects across models, without the pigment effects of the full hormone, and framed it as early-stage potential rather than settled human use. PMID 18612139. https://pubmed.ncbi.nlm.nih.gov/18612139/
BPC-157 and TB-500 given together
Achilles tendon repair in rats (Joint Diseases and Related Surgery, 2026). The only study we found that combined any of these four. Thirty-two rats had an Achilles tendon cut and repaired, then got BPC-157, TB-500, both, or nothing for four weeks. Both single compounds were linked to better tendon structure than controls, and only TB-500 reached a significant strength result. The combination gave no added benefit over either compound alone. The paper describes its TB-500 as synthetic thymosin beta-4 and does not say whether it was the full-length peptide. KPV and GHK-Cu were not part of it. PMID 42542926. https://pubmed.ncbi.nlm.nih.gov/42542926/
Etched Research supplies KLOW Blend as a lyophilized powder for laboratory research. The KLOW Blend 80mg product page lists its identity data and storage.
How it works
There is no single mechanism for KLOW, because KLOW is not a single compound. There are four mechanisms, each proposed for a different peptide, and each still being mapped.
BPC-157 has been linked in animal work to new blood vessel formation, with researchers reporting raised VEGF during muscle and tendon repair (Brcic et al., 2009). Thymosin Beta-4 binds actin, a structural protein inside cells, and the research ties that to cell migration and to new vessel growth at a wound edge. GHK-Cu carries a copper ion, and the copper appears to be doing much of the work, shifting the enzymes that build and reshape the extracellular matrix. KPV appears to quiet two inflammation switches called NF-kB and MAPK, which lowers the output of inflammatory messengers.
Read those four together and a reader will notice they touch related territory. Repair signaling, vessel growth, matrix building, inflammatory tone. That observation is not a finding. Nobody has run the experiment that would turn it into one, and the honest position is that four mechanisms described separately in separate models remain four separate mechanisms until something tests them as a group. The one study that paired two of them found no added effect.
What the research does not establish
The honest limits are the whole point here, and for a blend they are larger than for a single compound.
- No study has tested these four compounds together. Not in people, not in animals, not in cells. Every citation above concerns one compound on its own, except one rat study of two of them. Any account of how the four behave as a group is inference.
- A combination is not the sum of its parts. Compounds can interfere with each other, compete for the same transport, or change each other’s stability in solution. None of that has been characterized for this blend.
- Most of the underlying work is preclinical. BPC-157, GHK-Cu, and KPV rest almost entirely on animal and lab-dish models. Thymosin Beta-4 has the most human data, and even that is early trial work on wounds and eye surfaces rather than on anything else.
- None of the four is an FDA-approved drug. No approved human use exists for any component of this blend.
- Animal and cell results do not transfer. What happened in a mouse colitis model or a dish of irradiated fibroblasts does not tell you what would happen in a person.
- Nothing here is a safety conclusion. This is a research summary, not evidence that any of it is safe to use, alone or combined.
Anyone telling you the combination is proven is ahead of the research, and quite a long way ahead of it.
Common questions
Is KLOW FDA approved?
No. KLOW is a blend name, not a drug, and we found no approval anywhere for any of its four components. For BPC-157, the FDA’s compounding page says the agency lacks sufficient information to know whether it would cause harm in people (FDA). The human trials of full-length thymosin beta-4 are Phase 2 (Sosne and Ousler, 2015).
What is the difference between KLOW and GLOW?
They are vendor names for blends that share components. GLOW is GHK-Cu 50mg, BPC-157 10mg and TB-500 10mg, 70mg in total. KLOW is the same three plus KPV 10mg, 80mg in total. Etched Research also sells BPC-157 and TB-500 alone as a 20mg blend. No published study has compared these blends. The only published study of any of these pairings is a 2026 rat study of BPC-157 and TB-500 together, which found no added benefit over either one alone (Biçer et al., 2026). KPV’s own research is on gut inflammation in cells and mice (Dalmasso et al., 2008).
What side effects has KLOW research recorded?
None, because no study has given the four together. Records exist for some components on their own. A 2025 systematic review found no clinical safety data for BPC-157 (Vasireddi et al., 2025). The 72-person thymosin beta-4 dry eye trial reported no adverse events over 28 days of an eye solution (Sosne and Ousler, 2015). The KPV and GHK-Cu studies cited on this page are cell and animal work, so they give no side-effect record in people. None of this is a safety conclusion, alone or combined.
Last reviewed 2026-09-24.
For Research Use Only. Not for human consumption. Etched Research supplies compounds for laboratory and research use only. Nothing on this page is medical advice, a health claim, or a recommendation to use.
Available at Etched Research. Supplied as a pre-blended single vial. No independent lab report is on file for this compound. For research use only. View product →